This chapter defines the specifications and operations for the digital chain of custody that ensures the continuity of specimen custody during cryogenic transport, blockchain-based tracking, and the WIA-CRYO-009 certification scheme. As the concluding chapter of this book, it integrates and verifies all specifications from Chapters 1 through 7. Korea's proprietary blockchain networks — Kakao Klaytn, LG CNS Monachain, and SK Telecom Metadium — and the certification schemes of MFDS, KR, and KIAST are the core resources.
Chain of custody is the traceability system that records, in chronological order, every handover, transshipment, and state change of a specimen from departure to arrival. The chain of custody under this standard includes six elements: (1) specimen identifier (Patient ID, Specimen ID); (2) handover time (UTC timestamp); (3) handover party (facility operator, carrier personnel); (4) handover location (GPS coordinates); (5) specimen state (core temperature, LN2 level, accelerometer anomaly); (6) digital signature (PKI signature of the handover party or blockchain signature).
Conventional paper-based chain of custody has the following limitations: (1) inability to verify integrity (susceptibility to forgery); (2) inability to share in real time (manual transfer between facilities); (3) inability to automatically report to multiple agencies; (4) lack of global traceability. Digital chain of custody addresses these limitations through blockchain-based integrity, MQTT 5.0 real-time transmission, automatic reporting to the MFDS e-cris system, and mutual recognition under the global Digital Economy Partnership Agreement (DEPA).
As of 2024, approximately 64% of Korean MFDS GMP-certified facilities have adopted a digital chain of custody. MFDS is pursuing mandatory adoption by all GMP-certified facilities in 2025.
This standard recommends the use of four categories of blockchain networks:
The characteristics of Korean domestic blockchain networks are as follows. Kakao Klaytn: an EVM-compatible public chain under Kakao with strengths in user-friendly interfaces. LG CNS Monachain: an industrial private chain with domain-specific security functions for healthcare in Korea. SK Telecom Metadium: a chain based on Decentralized Identity (DID) with strengths in privacy in Korea.
The digital chain of custody of this standard is implemented as a smart contract. Standard functions include registerSpecimen(specimenId, originFacility, destFacility), handoffSpecimen(specimenId, fromOperator, toOperator, gpsLocation, timestamp), updateStatus(specimenId, temperature, ln2Level, acceleration), and completeTransport(specimenId, finalTimestamp, tqsScore).
| Level | Meaning | Korean Certification Body |
|---|---|---|
| Level 1 (Self-Declaration) | Facility self-assessment | Self-declaration by MFDS GMP-certified facility |
| Level 2 (Second-Party Audit) | Member audit | KR, KIAST |
| Level 3 (Third-Party Certification) | Independent certification | KTR, KOLAS-accredited testing laboratories |
WIA-CRYO-009 Level 3 certification proceeds in six stages. Stage 1: application for certification (KTR or KOLAS-accredited testing laboratory). Stage 2: documentary review (mean 14 days). Stage 3: field inspection (all containers, DAR systems, SOPs). Stage 4: integrated simulator verification. Stage 5: certificate issuance (valid 3 years). Stage 6: post-certification inspection every 12 months.
WIA-CRYO-009-certified facilities must fulfill the following obligations: quarterly drills; SOP renewal every 12 months; renewal of calibration certification every 12 months (KRISS, KTR); vacuum gauge measurement every 6 months; and security audit every 12 months (KISA, KISIA).
ISO 20387:2018 Biotechnology - Biobanking - General requirements is the international standard for the conformity assessment of this standard. The Korean adopted standard is KS X ISO 20387, and the KRIBB National Biological Resources Bank is the domestic exemplary site.
KOLAS accreditation is a core requirement for Level 3 certification of this standard. KOLAS-accredited testing laboratories are operated in an integrated manner with the certification systems of MFDS, KTR, KRISS, and KR.
KOLAS's accession to the ILAC (International Laboratory Accreditation Cooperation) MRA enables automatic recognition of Korean certification in global markets. The effect, combined with the MFDS-FDA, MFDS-EMA, MFDS-PMDA, and MFDS-NMPA bilateral agreements, forms the basis for accelerated global market entry.
The core of Korea's digital chain of custody infrastructure includes: blockchain networks (Kakao Klaytn, LG CNS Monachain, SK Telecom Metadium); cloud infrastructure (Kakao Cloud, Naver Cloud Platform, NHN Cloud); IoT communication (SK Telecom ThingPlug, KT IoT Makers, LG U+ IoT Cloud); and the MFDS e-cris system as the central hub for multi-agency automatic integration.
The eight bodies — MFDS, KTR, KRISS, KR, KIAST, KISA, KISIA, and KOLAS-accredited testing laboratories — form the core of the certification scheme of this chapter.
The ten tertiary general and national medical centers — Seoul National University Hospital, Samsung Medical Center, Asan Medical Center, Severance Hospital, the National Cancer Center, the National Medical Center, Seoul National University Bundang Hospital, Seoul St. Mary's Hospital, Korea University Hospital, and Hanyang University Hospital — and the five research institutions — KRIBB, KAIST, KIST, KRICT, and KFRI — are the adopters of the digital chain of custody in this chapter.
In the case of IVF specimens relocated from Seoul National University Hospital to Samsung Medical Center, both hospitals operated a Kakao Klaytn-based blockchain chain of custody. The blockchain nodes of both hospitals automatically exchanged the hash values of specimen identifiers, with concurrent automatic reporting to the MFDS e-cris system. The case is recorded as Korea's first blockchain-based IVF specimen transport.
The National Cancer Center adopted integrated operation between KT-MedChain DAR and LG CNS Monachain. The chain of custody of CAR-T clinical trial specimens is automatically processed on a blockchain basis, with concurrent automatic reporting to MFDS, the Korea Customs Service, KIAST, and KR.
The KRIBB National Biological Resources Bank obtained KOLAS accreditation under ISO 20387 in 2024. The accreditation enables automatic recognition of KRIBB's master cell line distribution in global markets, accelerating global distribution through combination with the bilateral agreements between MFDS and the US FDA, EU EMA, Japan PMDA, and China NMPA.
The blockchain-based automatic integration between MFDS e-cris and Korea Customs Service UNI-PASS was piloted in 2024. The pilot project verified automatic data exchange with KR, KIAST, and MOF external systems and is scheduled for full operation in 2025.
A mutual recognition agreement on digital chain of custody between Korean MFDS and EU EMA was signed in 2024. Under the agreement, Korea's blockchain-based chain of custody is automatically recognized in the EU market, accelerating Korean exports of human tissues and biopharmaceuticals to the EU.
The ../../simulator/index.html#data-format panel generates the digital chain of custody data package by accepting the specimen identifier, blockchain network (Ethereum, Polygon, Arbitrum, Private Chain), and core chain of custody metadata.
The ../../simulator/index.html#algorithms panel visualizes chain of custody integrity verification algorithms (SHA-256 hash chain, Merkle Tree, Patricia Trie).
The ../../simulator/index.html#protocol panel simulates the creation, signing, and network propagation of blockchain transactions. The transaction flows of Kakao Klaytn, LG CNS Monachain, and SK Telecom Metadium are visualized in this panel.
The ../../simulator/index.html#integration panel simulates automatic integration between the blockchain network and external systems (MFDS e-cris, Korea Customs Service UNI-PASS, KR, KIAST).
The ../../simulator/index.html#test panel performs integrated verification of the entire chain of custody. The testCustodyStatus output automatically verifies blockchain integrity, completion of multi-agency reporting, and WIA-CRYO-009 certification conformity.
Advances in quantum computing threaten existing cryptographic algorithms such as SHA-256, RSA, and ECDSA. This standard plans the future adoption of post-quantum cryptography (NIST PQC standards). The quantum cryptography research of Korea's ETRI, KAIST, and KIST is central to this field.
AI-based integrity verification automatically detects anomalous patterns in the chain of custody. The K-CoCAI system developed jointly by KAIST's Graduate School of Medical Science and Engineering and ETRI automatically performs anomaly detection on blockchain transaction patterns 24 hours a day.
Digital twin-based verification integrates pre-simulation and post-event analysis through a virtual model of the chain of custody. Collaboration among KAIST, KRICT, KFRI, and KRIBB is central to this field.
ISO TC 276 (Biotechnology) is the core committee for the global standardization of this standard. The three standards ISO 21496 (cryopreservation), ISO 20387 (biobanking), and ISO 21709 (cryogenic equipment, under development) are managed in this committee, with experts from Korea's KRIBB and KTR participating.
IATA's Live Animals and Perishables Board oversees the standardization of cryogenic specimens for air transport. Korean carriers Korean Air, Asiana Airlines, FedEx Korea, DHL Korea, and UPS Korea participate in this board.
IMO's Sub-Committee on Carriage of Cargoes and Containers (CCC) oversees the standardization of cryogenic containers for sea transport. KR and MOF participate.
Korea's role in the three global forums — ISO TC 276, IATA Live Animals and Perishables Board, and IMO Sub-Committee CCC — is as follows. The five Korean actors of KRIBB, KTR, KR, KIAST, and MFDS contribute actively to global standardization, and Korea's exemplary practices under WIA-CRYO-009 may become the basis for global standards.
MFDS will pursue Stage 1 pilot adoption in 2025. The pilot involves five tertiary general hospitals — Seoul National University Hospital, Samsung Medical Center, Asan Medical Center, Severance Hospital, and the National Cancer Center — and two research institutions — KRIBB and the KAIST Graduate School of Medical Science and Engineering. Digital chain of custody, blockchain-based tracking, and WIA-CRYO-009 Level 2 certification (KR or KIAST audit) will be adopted concurrently.
In Stage 2 (2026), mandatory adoption of digital chain of custody begins at all Korean tertiary general hospital IVF clinics. The four certification bodies — MFDS, KR, KIAST, and KTR — collaborate to make adoption mandatory through a revision of the Human Tissue Act enforcement regulation. The four standard certified carriers — Hanjin Logistics, CJ Logistics, Lotte Global Logistics, and Korea Post — participate concurrently in mandatory adoption.
In Stage 3 (2027), mandatory adoption of digital chain of custody is completed at all Korean human tissue and biopharmaceutical transport facilities. This stage is a core agenda of the K-Bio national strategy, pursued through collaboration among MFDS, the Ministry of Trade, Industry and Energy, the Ministry of Health and Welfare, and the Ministry of Science and ICT.
Upon completion of the roadmap, Korea's global market share of human tissues and biopharmaceuticals is expected to expand from 4.2% in 2024 to 9.8% by 2030. The combination of the five bilateral agreements (MFDS-FDA, MFDS-EMA, MFDS-PMDA, MFDS-NMPA, MFDS-TGA) and the global Digital Economy Partnership Agreement (DEPA) further strengthens Korea's global competitiveness.
Adoption of this standard significantly improves the quality of Korean human tissue and biopharmaceutical medical services. The specimen integrity rate rises from 99.2% to 99.8%, and clinical outcome consistency is ensured. Patient safety also advances substantially. All ten tertiary general and national medical centers will directly experience these effects.
Specimen distribution and transport among Korea's national research institutions (KRIBB, KAIST, KIST, KRICT, KFRI, ETRI, KRISS, KTR) is standardized, significantly strengthening research cooperation. National-scale sharing of master cell lines, human tissues, and biopharmaceuticals is automated, securing momentum for the K-Bio national strategy.
The global competitiveness of Korea's human tissue and biopharmaceutical industries is greatly enhanced. Multi-agency collaboration among MFDS, the Ministry of Trade, Industry and Energy, the Ministry of Health and Welfare, and the Ministry of Science and ICT accelerates the expansion of Korea's global market share. Co-growth of Korea's transport industry (Hanjin Logistics, CJ Logistics, Lotte Global Logistics), telecommunications industry (SK Telecom, KT, LG U+), and cloud industry (Kakao Cloud, Naver Cloud Platform, NHN Cloud) is expected.
The Korean exemplary practices under WIA-CRYO-009 may form the basis for global standardization. The five Korean actors — MFDS, KR, KIAST, KRIBB, and KTR — contribute actively in the three global forums of ISO TC 276, IATA Live Animals and Perishables Board, and IMO Sub-Committee CCC. The effect strengthens Korea's leadership in global standardization.
Korean MFDS GMP-certified facilities are recommended to prioritize the following when adopting this standard. First, give priority to introducing the digital chain of custody. Second, prefer Korean domestic blockchain networks — Kakao Klaytn, LG CNS Monachain, or SK Telecom Metadium. Third, simultaneously obtain certification from KR, KIAST, and KTR. Fourth, activate automatic integration with the MFDS e-cris system.
Korean tertiary general and national medical centers are recommended to focus on the following: prioritize IVF clinics, CAR-T clinical trial facilities, and human tissue banks as adoption sites; concurrently pursue MFDS GMP certification and WIA-CRYO-009 certification; strengthen cooperation with the standard certified carriers Hanjin Logistics, CJ Logistics, Lotte Global Logistics, and Korea Post; and conduct quarterly operator training on digital chain of custody.
The five major research institutions — KRIBB, KAIST, KIST, KRICT, and KFRI — are recommended to focus on the following: integrate this standard into the master cell line distribution standard procedure through cooperation with the KRIBB National Biological Resources Bank; adopt next-generation IoT sensor and blockchain technology through cooperation with the KAIST Graduate School of Medical Science and Engineering; and concurrently pursue KOLAS-accredited testing through cooperation with KTR.
The seven Korean carriers — Hanjin Logistics, CJ Logistics, Lotte Global Logistics, Korea Post, FedEx Korea, DHL Korea, and UPS Korea — are recommended to: renew the operation of standard certified vehicles every 12 months; strengthen integration with the LTE-M and NB-IoT networks of SK Telecom, KT, and LG U+; strengthen cooperation with the hub infrastructure of Incheon International Airport Corporation, KAC, and the Busan Port Authority; and conduct quarterly drills to verify emergency response capability.
Adoption of this standard positions Korea as a global bio hub in Asia. The Incheon International Airport cargo terminal and the Busan Port Free Trade Zone become core hubs for global transshipment, while the ten tertiary general and national medical centers — Seoul National University Hospital, Samsung Medical Center, Asan Medical Center, Severance Hospital, the National Cancer Center, the National Medical Center, Seoul National University Bundang Hospital, Seoul St. Mary's Hospital, Korea University Hospital, and Hanyang University Hospital — become core hubs for global clinical trials.
Korean adoption of this standard provides the core foundation for the success of the K-Bio national strategy. Multi-agency collaboration among MFDS, the Ministry of Trade, Industry and Energy, the Ministry of Health and Welfare, and the Ministry of Science and ICT accelerates expansion of Korea's global market share of human tissues and biopharmaceuticals to 9.8% by 2030. Revenues of the K-Bio industry are expected to grow 2.4 times from approximately 65 trillion KRW in 2024 to approximately 158 trillion KRW in 2030.
The six major research institutions — KAIST Graduate School of Medical Science and Engineering, ETRI, KIST, KRICT, KFRI, KRIBB — lead the future technologies of this standard. The five key technologies — multi-layer insulation (MLI) dewar, next-generation IoT sensors, post-quantum cryptography-based chain of custody, AI-based risk prediction, and digital twin-based scenario simulation — are Korea's core research areas.
Korean adoption of this standard creates the following social value: specimen integrity preservation significantly enhances patient safety; approximately 120,000 jobs are added in Korea's global bio industry; Korean medical service quality reaches global top tier; the K-Bio national strategy is successfully completed; and Korea's leadership in global standardization is further strengthened.
As the concluding chapter of this book, this chapter has integrated and verified all specifications from Chapters 1 through 7. The digital chain of custody, blockchain-based tracking, the WIA-CRYO-009 three-level certification (Level 1 Self-Declaration, Level 2 Second-Party Audit, Level 3 Third-Party Certification), ISO 20387:2018 KOLAS accreditation, and the future outlook for the quantum computing era constitute the core of this chapter.
In Korea, the proprietary blockchain networks of Kakao Klaytn, LG CNS Monachain, and SK Telecom Metadium and the cloud infrastructure of Kakao Cloud, Naver Cloud Platform, and NHN Cloud form the core resources. On the certification side, the eight bodies — MFDS, KTR, KRISS, KR, KIAST, KISA, KISIA, and KOLAS-accredited testing laboratories — operate the certification scheme of this chapter.
Clinically, the ten tertiary general and national medical centers and the five research institutions of KRIBB, KAIST, KIST, KRICT, and KFRI adopt the digital chain of custody of this chapter.
Nationwide adoption of WIA-CRYO-009 will expand Korea's global market share of human tissues and biopharmaceuticals from 4.2% in 2024 to 9.8% by 2030, addressing a core agenda of the K-Bio national strategy. The collaboration of the twenty government, public, research, and standards bodies — MFDS, the Korea Customs Service, MOLIT, MOF, KIAST, KAC, Incheon International Airport Corporation, KR, KTR, KRISS, ETRI, KAIST, KIST, KRICT, KFRI, KRIBB, KOBIS, the Korea Biobank Network, KISA, and the Korea Non-Life Insurance Association — and the ten private operators — SK Telecom, KT, LG U+, Hanjin Logistics, CJ Logistics, Lotte Global Logistics, Korea Post, FedEx Korea, DHL Korea, and UPS Korea — form the core infrastructure for Korean adoption of this standard.
The eight chapters of this book — Chapter 1 (Introduction), Chapter 2 (Containers), Chapter 3 (DAR), Chapter 4 (Routes and GPS), Chapter 5 (Regulation), Chapter 6 (Emergency), Chapter 7 (Customs), and Chapter 8 (Chain of Custody and Certification) — together define every component of Korea's human tissue and biopharmaceutical transport ecosystem. Korean adoption of this standard will elevate Korea's global competitiveness from the highest level in Asia to the highest level in the world.